Peer-Reviewed EMERGENT-2 Trial Data Supports Xanomeline-Trospium for Schizophrenia
In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.
Source: hcplive.com
